Prescription of antibiotics in patients with febrile illness is high.
Malaria remains the most prevalent vector-borne infectious disease and has the highest rates of fatality. Current antimalarial drug strategies cure malaria or prevent infections but lack a sustained public health impact because they fail to expedite the acquisition of protective immunity.
This review will describe the effect of classical antibacterial agents against malaria parasites and the use of some of these compounds in clinical settings.
Almost one million people die of severe malaria every year. In recent years, artemisinin-based combination therapies have become the backbone of the treatment of uncomplicated falciparum malaria and have helped to reduce the burden of malaria in large parts of the malaria-endemic world. However, the treatment of severe malaria,the clinical syndrome responsible for most malaria-associated deaths, remains largely unaffected by this development.